Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DF4101
- Development stage
- Discontinued
- Lead developer
- AbbVie
- Modality
- Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**DF4101 (ABBV-303)** is a trispecific natural killer (NK) cell engager antibody developed using Dragonfly Therapeutics' TriNKET platform, originally discovered by Dragonfly and now advanced by AbbVie. It simultaneously binds CD16a (on NK cells for activation), NKG2D (co-activating NK receptor), and c-Met (tumor antigen), enabling potent NK cell, γδ T cell, and CD8+ T cell-mediated antitumor activity against solid tumors expressing c-Met, including those with low or heterogeneous expression. Administered intravenously, it is in early clinical testing for relapsed/refractory advanced solid tumors.[1][3][5]
- Other names
- c-Met-targeting tri-specific natural killer cell engager ABBV-303
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)NKG2D (Natural killer group 2 member D receptor)MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on DF4101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DF4101.